The NHS could save £4m a year by offering women with low-risk breast cancer a genetic test that could allow them to avoid toxic and unnecessary chemotherapy.
The test – called Prosigna – is currently only approved for use in post-menopausal women whose cancer has spread to no more than three nearby lymph nodes.
But experts at University College London say offering the test more widely, to women as young as 40, could save the NHS £654 per patient.
It could also spare more than 4,000 women a year the side effects of chemotherapy, which can include nausea, vomiting, hair loss and an increased
To provide well-rounded coverage and a breadth of insight across various events, we rely on contributions from several staff writers, each bringing their own area of expertise to our publication.